home > Program


Sicentific Program(Day 1/Day 2)

연수평점 : 최대 8점(2일간)

Time Program Speaker
07:30 - 11:00 Registration  
07:50 - 11:40 A-Cap / K-Cap Meeting  
10:50 - 12:00 Poster Viewing Session  
12:00 - 13:00 Lunch  
13:00 - 13:05 Opening Ceremony Ji Youl LEE
(President of KPS and APSU)
13:05 - 13:10 Congratulation Remark Distinguished Guests
13:10 - 14:50 Session I: Prostate Cancer I Hideyuki AKAZA (Japan),
Chun Il KIM (Korea)
20 Radical Prostatectomy in North America: Current Trends and Future Direction Matthew R. COOPERBERG (USA)
20 Strengths and Limitations of MRI for Interrogation of the Prostate Robert E. REITER (USA)
20 Genomic Tests for Prostate Cancer Stephen J. FREEDLAND (USA)
20 Early Detection of Prostate Cancer in the United States Peter R. CARROLL (USA)
20 Panel Discussion Sung Soo JEON (Korea),
Hong Gee SIM (Singapore),
Jun Hyuk HONG (Korea),
Bannakij LOJANAPIWAT (Thailand),
Giuseppe PROCOPIO (Italy),
Sung Kyu HONG (Korea),
Shigeo HORIE (Japan),
Woong Kyu HAN (Korea)
14:50 - 15:55 Session II: Kidney Cancer I Choung-Soo KIM (Korea),
Lukman HAKIM (Indonesia)
20 The Role of Peri-Operative Systemic Therapy in Renal Cell Carcinoma Peter F.A. MULDERS (Netherlands)
15 Biomarkers for Optimal Patient Selection of Systemic Therapy in mRCC Jae Young PARK (Korea)
15 Current and Future Application of Immune Check Point Inhibitors Yu Jung KIM (Korea)
15 Panel Discussion Jacob See-Tong PANG (Taiwan),
Sang Hyeon CHEON (Korea),
Rainy UMBAS (Indonesia),
Seong Il SEO (Korea),
Seung-Ju LEE (Korea),
Teng Aik ONG (Malaysia),
Seung Hyun JEON (Korea),
Peter F.A. MULDERS (Netherlands)
15:55 - 16:15 Coffee Break  
16:15 - 17:30 Session III: Bladder Cancer I Tag Keun YOO (Korea),
Bannakij LOJANAPIWAT (Thailand)
20 Clinical Applications from the TCGA Project Seth P. LERNER (USA)
15 The Evidence for the Extent of Lymphadenectomy during Radical Cystectomy Bumsik HONG (Korea)
15 Bladder-Sparing in Muscle Invasive Bladder Cancer: Selection and Optimal Treatment Jong Jin OH (Korea)
15 Neoadjuvant and Adjuvant Therapy: Current Indications, Trials, and Patient Selection Dong Hyun LEE (Korea)
10 Panel Discussion Wun-Jae KIM (Korea),
Eddie CHAN (Hong Kong),
Moon Ki JO (Korea),
Robert E. REITER (USA),
Hong Seok PARK (Korea),
Hong Gee SIM (Singapore),
Jun Hyun HAN (Korea),
17:30 Welcome Dinner  
Time Program Speaker
08:30 - 09:00 Registration
09:00 - 10:00 Session IV: Potpourri: Issues to Consider Hong Gee SIM (Singapore),
Kyung Seop LEE (Korea)
15 Management of Lymph Node-Positive Penile Cancer In Ho CHANG (Korea)
15 Contemporary Retroperitoneal Lymph Node Dissection for Testis Cancer Myungsun SHIM (Korea)
15 Tamsulosin 0.4mg use in Asian Patients U-Syn HA (Korea)
15 Panel Discussion Stephen J. FREEDLAND (USA),
Lukman HAKIM (Indonesia),
Tae Young JUNG (Korea),
Peter F.A. MULDERS (Netherlands),
Jung Sik HUH (Korea),
Giuseppe PROCOPIO (Italy),
Seung Chol PARK (Korea),
Bannakij LOJANAPIWAT (Thailand)
10:00 - 10:20 Coffee Break
10:20 - 11:40 Session V: Bladder Cancer II Eddie CHAN (Hong Kong),
Jae Il CHUNG (Korea)
20 NMIBC BCG Unresponsive Disease Seth P. LERNER (USA)
15 Urine Markers for Bladder Cancer Seok-Joong YUN (Korea)
15 Enhanced Technique Endoscopic Visualization in NMIBC Seok Ho KANG (Korea)
15 Role of IO in NMIBC Ho Kyung SEO (Korea)
15 Panel Discussion Giuseppe PROCOPIO (Italy),
Rainy UMBAS (Indonesia),
Young Sig KIM (Korea),
Peter F.A. MULDERS (Netherlands),
Bannakij LOJANAPIWAT (Thailand),
Shigeo HORIE (Japan),
Jeong Kyun YEO (Korea)
11:40 - 12:40 Lunch
12:40 - 14:15 Session VI: Prostate Cancer II Ji Youl LEE (Korea),
Shigeo HORIE (Japan)
15 Focal Therapy Eligibility Determined by mpMRI or mpMRI/US Fusion Biopsy Hwang Gyun JEON (Korea)
20 Molecular Imaging in the Management of Prostate Cancer Robert E. REITER (USA)
20 How to Manage Node-Positive Prostate Cancer Hong Koo HA (Korea)
15 Practical Guidance on the Comorbidity in the Treatment of mCRPC Jae Young JOUNG (Korea)
15 RANKL Inhibition as a Treatment Option in Preventing Skeletal-Related Events (SRE) in Patients with Bone Metastases in Prostate Cancer Won Sik JANG (Korea)
10 Panel Discussion Hideyuki AKAZA (Japan),
Taek Won KANG (Korea),
Giuseppe PROCOPIO (Italy),
Seth Paul LERNER (USA),
Kyo Chul KOO (Korea),
Jacob SeeTong PANG (Taiwan),
Sung Woo PARK (Korea),
Teng Aik ONG (Malaysia),
Jin Seon CHO (Korea)
14:15 - 14:35 Coffee Break
14:35 - 15:55 Session VII: Kidney Cancer II Hyun Moo LEE (Korea),
Rainy UMBAS (Indonesia)
20 Optimization of Imaging in Renal Tumors: Use of CAIX Antibody Peter F.A. MULDERS (Netherlands)
15 The Role of Arterial Embolization in RCCa Hyun Tae KIM (Korea)
15 Incidence of Benign Lesions among Small Renal Masses Treated with Surgery: Impact of Diagnostic Tests for Characterization In Gab JEONG (Korea)
20 Safety and Efficacy of Cabozantinib in Metastatic RenalCell Carcinoma: Real-World Data From an Italian Managed Access Program Giuseppe PROCOPIO (Italy)
10 Panel Discussion Cheryn SONG (Korea),
Lukman HAKIM (Indonesia),
Sung Hoo HONG (Korea),
Robert E. REITER (USA),
Jun Sung KOH (Korea),
Bannakij LOJANAPIWAT (Thailand),
Jae Sung LIM (Korea),
15:55 - 17:15 Session VIII: Prostate Cancer III Byung ha CHUNG (Korea),
Jacob See-Tong PANG (Taiwan)
20 Neoadjuvant Treatment Prior to Prostatectomy in HighRisk Disease Dalsan YOU (Korea)
15 Local Treatment in Patients with Newly Diagnosed Metastatic Disease: Myth or Reality? Se Yun KWON (Korea)
15 Current Management of Hormone Sensitive Prostate Cancer Seung Hwan LEE (Korea)
20 CRPC: Definition and Treatment Options Stephen J. FREEDLAND (USA)
10 Panel Discussion Shigeo HORIE (Japan),
Seth Paul LERNER (USA),
Jeong Seok HWA (Korea),
Hideyuki AKAZA (Japan),
Sun Il KIM (Korea),
Lukman HAKIM (Indonesia),
Soo Dong KIM (Korea),
Rainy UMBAS (Indonesia),
Young Hwii KO (Korea),
Sang Eun LEE (Korea)
17:15 Closing Remarks Ji Youl LEE
(President of KPS and APSU)